PEN

Based on Penumbra, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Penumbra, Inc. do?

Penumbra designs and manufactures medical devices used primarily in neurovascular and vascular procedures. Its products help physicians remove blood clots, treat brain aneurysms, and access complex intracranial anatomy. The company also develops computer-based rehabilitation technologies for neurological recovery.

Does PEN pay dividends?

No, Penumbra does not currently pay a dividend. The company reinvests available capital into product development, clinical expansion, and international growth — a common approach for medical device companies still scaling their commercial footprint.

When does PEN report earnings?

Penumbra reports on a quarterly cadence, as is standard for US-listed companies. For the exact schedule and most recent results, check Penumbra's investor relations page directly, as specific dates are subject to change.

Is PEN a good stock to buy?

UQS Score rates PEN as Good overall. Its strongest attributes are its Growth and Risk pillar ratings. The Valuation pillar is Elevated, which means the stock may already reflect high expectations. The full pillar breakdown is available to UQS Pro members.

Is PEN overvalued?

The UQS Valuation pillar for PEN is rated Elevated, suggesting the market has priced in strong future performance. Whether that premium is justified depends on how well the company executes on its growth trajectory — a question the full UQS analysis helps contextualize.

How does PEN compare to its competitors?

Penumbra's peers in the medical device space — including Globus Medical, Align Technology, and Insulet — each operate in distinct clinical niches. PEN differentiates itself through its neurovascular and aspiration thrombectomy focus. UQS Pro members can view side-by-side pillar comparisons.

What is PEN's market cap bracket?

Penumbra is classified as a large-cap company. This places it among the more established names in the medical device sector, though it remains smaller than the industry's largest diversified players.

Who founded Penumbra, Inc.?

Penumbra was founded in 2015. Founding details, including the names of its founders, are publicly available through the company's official filings and investor relations materials.

Is PEN a long-term quality investment?

From a long-term quality perspective, PEN's Strong Growth and Risk ratings are encouraging signals. However, the Neutral Moat rating suggests the company has not yet established the deep competitive barriers that typically define the most durable long-term holdings. The complete picture is available in the UQS Pro analysis.

What is the main competitive advantage of Penumbra?

Penumbra's edge lies in its specialized focus on aspiration-based thrombectomy and neurovascular access — a technically demanding niche requiring significant clinical validation and physician training. Its broad branded product portfolio across stroke and aneurysm care creates procedural familiarity among hospital teams.

What sector does PEN belong to?

Penumbra operates in the Healthcare sector, specifically within the medical devices and equipment industry. Its products address acute neurovascular conditions, placing it in a high-growth segment of the broader healthcare market.

Is PEN a growth stock or value stock?

Based on its UQS pillar profile, PEN leans firmly toward the growth category. Its Growth pillar is rated Strong while its Valuation pillar is Elevated — a combination typical of companies where investors are paying a premium in anticipation of continued expansion.

Penumbra, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.

Penumbra, Inc. is growing rapidly with strong revenue and earnings expansion.

Penumbra, Inc. carries minimal financial risk with conservative leverage and strong solvency.

Penumbra, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Penumbra, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PEN.

The UQS (Unified Quality Score) for Penumbra, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Penumbra, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Penumbra, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.